CapHorn Invest

We are proud to support Faircraft, a French startup pioneering in-vitro leather manufacturing, which has just finalized a €15 million Series A round alongside with Kindred Ventures Heirloom Entrepreneur First Blue Wire Capital Sake Bosch, Bpifrance. 🙌 🚀 This round of financing marks a key step in its ambition to transform the luxury fashion and leather goods industry through sustainable and ethical innovation. 💡 Why is this a major step forward ? ▫️ Environmental impact : Faircraft's process consumes 20 times less water and divides CO2 emissions by 10 compared to traditional leather. ▫️ Ethical solution : Offering an animal-friendly alternative that meets the expectations of new generations, particularly Generation Z. ▫️ Innovation for luxury : A new material, adapted to the creativity of premium brands and their sustainability requirements. 🎯 Next steps : ▫️ Recruit new talent to support industrial and commercial development. ▫️ Collaborate with leading luxury houses to refine products and meet designers' needs. ▫️ Open a factory in France within 2-3 years to produce on a large scale and achieve price parity with traditional leather. 👏 At CapHorn, we are convinced that Faircraft embodies the future of a more responsible and innovative industry. Congratulations to Haïkel Balti, Cesar VALENCIA GALLARDO, and the entire Faircraft team for this fundraising and their commitment to a sustainable future. 👉 Discover more about this industrial revolution : https://urlz.fr/t8hT #impact #startup #innovation Source : Maddyness 👇️

Osivax and Agriodor join the EIC Scaling Club 🚀 🌟 We're delighted to announce that Osivax and Agriodor, two CapHorn-funded companies, have been selected to join the prestigious EIC Scaling Club ! This selective program aims to accelerate the growth of Europe's most promising deep-tech companies. 📈 Thanks to this high-level support, these companies benefit from enhanced fund-raising, mentoring and connections with strategic partners. A major step in their development ! Congratulations to Osivax and Agriodor ! 👏 #innovation #privateequity #scalingclub #deeptech

Congratulations to the entire Therapixel team on this huge success ! 👏 ✅️ We are immensely proud to celebrate the 4th FDA approval of an AI medical device. 🩺 Their latest algorithm, which allows updates without new regulatory submissions thanks to its innovative PCCP, paves the way for rapid and flexible advances in medical diagnostics. A great step forward ! 🚀 #investment #health #innovation

Back to work season is here, but at CapHorn, there was no summer break for our portfolio companies. As many return to the office, we’re proud to see the companies we support continue to push boundaries and achieve significant milestones. Here are three standout successes from this summer : Impress is accelerating its growth in Europe with the strategic acquisition of DR SMILE, further cementing its position as a leader in the invisible orthodontics market. 🦷💪 Ledger has rewritten the rules of crypto-asset security with a strategic partnership with Revolut. This collaboration ushers in a new era of protection for cryptocurrency users, solidifying Ledger as a pillar of digital trust. 🔐 💳️ Wandercraft transcended the limits of mobility by enabling Kevin Piette and his exoskeleton to carry the Olympic flame at the Paris 2024 Games. This historic first redefines what is possible in augmented mobility. 🔥🤖 At CapHorn, we’re proud to see our companies not only rise to challenges but also transform industries and create new success stories. Welcome to the new season – there’s plenty to be excited about in the months ahead ! #CapHorn #Innovation #Tech #Entrepreneurship #SuccessStories

We are proud to announce that CapHorn has been recognized among the Top 30 French venture capital firms specializing in #Deeptech 🇫🇷 🔝 This distinction highlights our ongoing commitment to innovative companies in the fields of #AI, #Climatetech and #Deeptech. It's an honor to be cited alongside leaders such as Asterion Ventures, Resonance and many others who are shaping the future of technology in France. 🚀 From seed to Series C, we're here to accelerate the journey of French startups seeking transformation and innovation.  #FrenchVentureCapital #Innovation #Startups

Ledger and Worldia featured in French Tech Next 40/120 ranking 2024 🚀 📈 This ranking highlights the most promising companies in French tech. Together, the 120 companies selected have generated total sales in excess of 10 billion euros by 2023, and represent 40,000 direct jobs. Among these leaders, two startups in our portfolio, Ledger and Worldia, stand out in particular : 🔐 Ledger, world leader in digital asset security solutions, continues to revolutionize the crypto-security sector with its innovative products, guaranteeing maximum protection of crypto-currencies for millions of users worldwide. 🌍️ Worldia, a pioneer in the tourism sector, transforms travel experiences with its tailor-made travel offers. Using advanced technology, Worldia enables travelers to create personalized itineraries in just a few clicks, meeting the needs and desires of each individual. Well done to them ! 👏

New partnership between Posos and Ordoclic 🤝 💡 Posos and Ordoclic join forces to revolutionize medical prescribing with a new digital prescription solution. 📆 From July 2024, this innovation will be available to healthcare professionals, with widespread use scheduled for the end of December 2024. 👩⚕️ For doctors : automatic import of paper prescriptions, personalized pharmaceutical analysis and suggestions for therapeutic alternatives by Posos for optimal management. 📄 Key features : Creation of prescription templates, dematerialization of medical documents, patient forms and electronic signatures of consents thanks to Ordoclic. An essential tool for streamlining daily medical practice. 🛡️ Certification and support : This collaboration guarantees CNDA accreditation for Ségur and includes benefits such as the structure package, reinforcing support for doctors in their digital transition. Posos continues to expand its network, with recent partnerships with Qare, Rofim and Alphega Pharmacie, reinforcing its commitment to innovation in healthcare. 🚀 #health #collaboration #medical #innovation

Qare joins forces with Posos 🚀 🙌 We are proud to announce that Posos, one of our portfolio's companies, has taken a major step forward by joining forces with Qare, a pioneer in teleconsultation. ✅ This collaboration will enable the integration of Posos' medication database, recently approved by the French National Authority for Health (Haute Autorité de Santé), into Qare's system. ⛑ This initiative aims to provide healthcare professionals with precise tools for managing medications and personalizing prescriptions, thereby improving the quality of care delivered. A significant advance in the interface between technology and healthcare ! 👏 #health #collaboration #teleconsultation

Wandercraft receives €25 million in financing from the European Investment Bank (EIB) 🚀 💸 We're proud to share another significant milestone for Wandercraft, a startup in our portfolio, which has just obtain an impressive €25 million in financing from the European Investment Bank (EIB) and the European Commission. 🤖 This support from EIB is aimed at developing an innovative new personal exoskeleton and widening access to the Atalante X, their revolutionary exoskeleton already in use in nearly 100 rehabilitation and clinical research centers in Europe and the USA. 💡 Wandercraft's ongoing commitment to improving patients' lives and making daily mobility an accessible reality is not only inspiring but aligned with our values of innovation and social impact. Their recent FDA clearance and the introduction of their next-generation exoskeletons demonstrate the transformative impact of their technology. 👏 We can't wait to find out what happens next ! #investment #innovation #europe #medtech 

Osivax successfully completes phase 2a trial for promising OVX836 vaccine 💉 👏 Congratulations to Osivax on the completion of the Phase 2a trial of OVX836 with VQI, marking significant progress towards a breakthrough influenza vaccine. This advance, involving 478 participants in Australia, evaluates OVX836's potential to offer prolonged protection against influenza A. 🙌 Many thanks to the participants and research teams. The results expected by the end of 2024 promise to reinforce our mission of investing in tomorrow's healthcare. #Osivax #HealthInnovation #CapHorn